

# Controlled Dangerous Substances Guide

(DRAFT)

New Jersey Institute of Technology

Environmental, Health and Safety Department

University Heights,

Newark, NJ 07102-1982

(973) 596-3059

September 2019

March 2021



#### NEW JERSEY INSTITUTE OF TECHNOLOGY

University Heights, Newark, New Jersey 07102

#### **Document Control No.:**

**Document Title: Controlled Dangerous Substances Guide** 

#### Introduction

New Jersey Department of Consumer Affairs (NJ DCA) Drug Control Unit and the United States Department of Justice, Drug Enforcement Administration (US DEA) have made certain restrictions regarding purchase, use and disposal of controlled dangerous substances (CDS) as defined in N.J.S.A. 24:21-2. These regulations and procedures have been passed in order to prevent diversion and abuse of controlled substances. The laboratory use of controlled substances is to be monitored by the Environmental Health and Safety Department (EHS) at NJIT. EHS department will assist researchers in conveying the responsibilities of each individual and department. EHS ensures NJIT will comply with federal and state regulations.

#### **New Jersey Registration Regulations and Agencies**

The State of New Jersey has established a Drug Control Unit within the Department of Law and Public Safety, for the purpose of assisting in the enforcement of those provisions of the New Jersey Controlled Dangerous Substances ("C.D.S") Act which relate to persons who, or firms that, manufacture, prescribe, distribute, dispense or conduct research or analysis utilizing controlled substances (DCA NJ Drug Control Unit).

#### Definitions<sup>1</sup>

Certain drugs and chemicals are classified by the Drug Enforcement Administration (DEA) into 5 categories based upon acceptable medical use and the drug's abuse or dependency potential.

A list of CDS classified in different categories could be found in <u>New Jersey Controlled Dangerous</u> Substances Act. DEA Controlled Substances (Orange Book)

<sup>&</sup>lt;sup>1</sup> List of Controlled Substances:

Substances not listed as a controlled substance might be considered a Schedule I or II substance in a criminal prosecution. Any substance made for human use and similar to Schedule I or Schedule II substances is not approved in the United States.

#### Schedule I

The substance: (1) has high potential for abuse; and (2) has no accepted medical use in treatment in the United States; or lacks accepted safety for use in treatment under medical supervision.

Examples: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4methylenedioxymethamphetamine (ecstasy), methagualone, and peyote

#### Schedule II

The substance: (1) has high potential for abuse; (2) has currently accepted medical use in treatment in the United States, or currently accepted medical use with severe restrictions; and (3) abuse may lead to severe psychic or physical dependence.

Examples: Combination products with less than 15 milligrams of hydrocodone per dosage unit (Vicodin), cocaine, methamphetamine, methadone, hydromorphone (Dilaudid), meperidine (Demerol), oxycodone (OxyContin), fentanyl, Dexedrine, Adderall, and Ritalin

#### Schedule III

The substance: (1) has a potential for abuse less than the substances listed in Schedules I and II; (2) has currently accepted medical use in treatment in the United States; and (3) abuse may lead to moderate or low physical dependence or high psychological dependence.

Examples: Products containing less than 90 milligrams of codeine per dosage unit (Tylenol with codeine), ketamine, anabolic steroids, testosterone

#### Schedule IV

The substance: (1) has low potential for abuse relative to the substances listed in Schedule III; (2) has currently accepted medical use in treatment in the United States; and (3) may lead to limited physical dependence or psychological dependence relative to the substances listed in Schedule III.

Examples: Xanax, Soma, Darvon, Darvocet, Valium, Ativan, Talwin, Ambien, Tramadol

#### Schedule V

The substance: (1) has low potential for abuse relative to the substances listed in Schedule IV; (2) has currently accepted medical use in treatment in the United States; and (3) has limited

physical dependence or psychological dependence liability relative to the substances listed in Schedule IV.

Examples: cough preparations with less than 200 milligrams of codeine or per 100 milliliters (Robitussin AC), Lomotil, Motofen, Lyrica, Parepectolin

#### Registration and Authorized Use<sup>2</sup>

According to the <u>Controlled Dangerous Substance Registration form</u> provided by New Jersey Office of the Attorney General, all individuals, or firms, that manufacture, prescribe, distribute, dispense or conduct research or analysis utilizing controlled dangerous substances are required to register using the form provided in the link above. The cost of registration could be found in the form. The application process could take up to 4 to 6 weeks.

Researchers with protocols approved by the EHS are required to have a valid DEA License and comply with all applicable regulations. Individuals are required to have both federal and state registration certificates for their research. The exact location where the substance(s) is stored, prescribed, used, or dispensed has to be provided. Each location or room needs a separate application submitted and registration obtained. The name of the individuals handling the substance(s) has to be used and not the name of institute or any other entity or department.

All CDS users have to inform EHS of any alterations to their programs and have to maintain their license. Licenses have to be renewed annually.

The use of CDS on animals has to be reviewed by Rutgers' Institutional Animal Care and Use Committee (IACUC). The Controlled Dangerous Substances Registration form is to be submitted after the approval of the protocols by the IACUC.

An inspection by the Drug Control Unit shall be conducted prior to approval of the application.

Note: §1308.23 Exemption of certain chemical preparations; application. (https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308 23.htm)

Note: §1308.31 Application for exemption of a nonnarcotic prescription product.

https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308 31.htm

New Jersey Administrative Code – Controlled Dangerous Substances:

https://www.njconsumeraffairs.gov/regulations/Chapter-45H-Controlled-Dangerous-Substances.pdf

<sup>&</sup>lt;sup>2</sup> Note: Annual fee at the time of application or for renewal for practitioners conducting research with controlled dangerous substances at the moment is \$20.

#### **Employee Questionnaire**

Diversion Control Division of DEA, US Department of Justice, states that obtaining certain information by non-practitioners is important to assess the likelihood of users and employees committing a drug security breach.

Employees are required to complete an Employee Questionnaire form authorizing entities, such as NJIT, to make inquiries of courts and law enforcement agencies for possible pending charges or convictions. This information will remain confidential and will be used discreetly.

#### **Receipt of DEA Shipments**

Order forms are required to be kept for two years or longer to satisfy recordkeeping provisions. A person registered with the DEA can use either a DEA Form 222 or an electronic order to distribute a Schedule I or II to another registered or authorized user for furthering the chemical analysis, instructional activities, or research.

The theft or loss of any used or unused order forms or other order related forms has to be reported to the Drug Control Unit upon discovery. The Drug Control Unit has to be informed of recovered or found forms that were reported stolen or lost.

#### **Purchasing Controlled Dangerous Substances**

EHS will review and approve the purchase of any controlled dangerous substances. A Controlled Dangerous Substance Request form has to be submitted to the EHS department. EHS will review the physical conditions of the storage place and the laboratory, confirm authorized users and Principal Investigators, and assess the protocols pertaining to the controlled substance under consideration before approval. The CDS vendor needs to be provided with proof of license and might require additional documents.

#### **Labeling and Packaging Requirements**

All containers have to be labeled with a symbol indicating the schedule in which the substance is listed. The symbol is to be located on the right upper corner of the label with a font at least two times as large as the largest type on the label. The label might also be printed on the label instead of the upper right corner, in which case the symbol must be printed at least one-half the height of the label and in a contrasting color.

The Globally Harmonized System (GHS) rules apply for labelling. The label should reflect the full name in English. Using abbreviations, chemical formulas, and other forms of identifications not approved of in GHS has to be avoided.

Schedule	Symbol
Schedule I	I or C-I
Schedule II	II or C-II
Schedule III	III or C-III
Schedule IV	IV or C-IV
Schedule V	V or C-V

The word "Schedule" does not need to be used.

Controlled substances must be segregated from all other materials and kept under constant surveillance during normal business hours.

#### Responsibilities

**DEA Registrant:** DEA registrant is the primary responsible party and has to conduct research responsibly and abide by regulations and policies. EHS monitors the registrant's activities which need to meet the requirements provided by law and this policy.

**Academic department chair(s):** The department chairs need to be aware of the research or teaching activities and the persons using departmental facilities that hold controlled substances. The Chair is responsible for reporting concerns to the EHS and the respective Dean.

**Dean of the College:** Dean of the college monitors the activities of registrants and other users and oversees proper use and security of laboratories and storage areas for controlled substances in cooperation with the EHS department.

**The Environmental Health and Safety Department:** EHS will conduct periodic inspections of activity and site reviews, assists in keeping activities in compliance with State and Federal laws, and assists with disposal of controlled substances. EHS may also assist with training and record keeping instructions.

The Public Safety Department: Any criminal activities related to the use of CDS has to be investigated by NJIT Public Safety. Public Safety is responsible for notifying the DEA, NJIT Human Resources, the Environmental Health and Safety department, the NJIT legal team and the President of NJIT. The Director of Public Safety, or designee, will be the point of contact with DEA in matters involving use of CDS in research or teaching labs.

**Purchasing Department:** The purchasing department is responsible for notifying NJIT EHS of any purchases related to CDS. These procurements have to be approved by EHS before being processed by

Purchasing. Researchers have to mention the purchase of Controlled Dangerous Substances. A copy of DEA registration has to be provided. Additional documents might be required.

**NJIT Office of Legal Counsel:** The Office of Legal Counsel is responsible for providing legal advice to different university bodies regarding CDS in research and teaching labs.

#### Record Keeping Requirements and Inventory Procedures<sup>3</sup>

Principal Investigator (PI) is responsible for documenting the inventory of all controlled substances and maintaining the records. The CDS records should be kept separately from other substances. The receipt of all CDS has to be documented. A chain of custody document has to be available showing the movement of substance from the point it is delivered to NJIT onwards. Chain of Custody must include the name of the PI, location, date, Vendor's DEA number, vendor's location and contact information, quantity and volume, and concentration. All documents have to be readily available upon request.

A log for the use of each substance must be kept for each container. This log contains the name of the PI, date of delivery, exact location, full name of the substance, volume and quantity, and concentration.

Every inventory and required record shall be kept by the registrant and be readily available for at least 2 years or longer. NJIT EHS shall have access to inventories and the records of the registrant.

All usage, waste, and damaged material have to be recorded. All incidents regarding CDS have to be reported to EHS and Public Safety and an incident report has to be submitted.

Each registered location and each activity requires a separate written inventory. Each inventory shall be kept at the related registered location. An inventory of the stocks of controlled substances on hand shall be taken on the day the researcher engages in controlled substances activities (Initial inventory date). The date a substance is actually received or transferred shall be used as the date of receipt or distribution of any documents. An inventory needs to be taken every two years following the date on which the initial inventory is taken by a registrant (Biennial inventory date).

**Note:** A registered person using any controlled substance in preclinical research or in teaching at a registered establishment, which maintains records with respect to such substances, is not required to keep records if he notifies the Drug Enforcement Administration and the Drug Control Unit of the name, address, and registration number of the establishment maintaining such records." (Chapter 45H, p. 26, section e). Notice required shall be given at the time the person applies for registration or reregistration and shall be made in the form of an attachment to the application, which shall be filed with the application.

<sup>&</sup>lt;sup>3</sup> **Note:** Sodium pentobarbital in animal euthanasia has specific requirements that needs to be adhered to.

#### **Controlled Substance Tracking**

Controlled substances need to be tracked after shipment. Upon arrival of any shipment of CDS, the substance has to be under surveillance of an authorized user. NJIT EHS and Public Safety are to be notified of the time and date of arrival.

In case the substance is not delivered directly to the designated laboratory, transferring a controlled substance from the point of arrival to the final destination for storage or laboratory work has to be done under the supervision of NJIT Public Safety and after approval of NJIT EHS. The material has to remain in a locked storage area until being transferred to the final destination.

#### **Security Requirements**

Small quantities of Schedule I or II substances shall be stored in a secured storage area.

- A safe or a steel cabinet with the following specifications: 30 man-minutes against surreptitious entry, 10 man-minutes against forced entry, 20 man-hours against lock manipulation, and 20 man-hours against radiological techniques. The safe or cabinet needs to be bolted or cemented to the floor so it cannot be removed if weighing less than 750 pounds. The safe or cabinet, depending on the quantities and type of controlled substances, might require an alarm system transmitting a signal to NJIT Public Safety, or a 24-hour control station operated by the registrant, upon unauthorized access.
- A vault might be used as an alternative. EHS shall review the requirements upon request.

Materials listed in Schedules III, IV, and V can be stored similar to Schedules I or II, or stored in a building or areas within a building that has walls or fences protecting the building from burglary and the doors can be securely locked during non-working hours. The building has to be equipped with an alarm system connected directly to the Public Safety, or a 24-hour control station managed by the registrant. Controlled substances must be segregated from all other materials and kept under constant surveillance during normal business hours.

The storage areas have to be accessible only to specifically authorized employees. When access to the area is necessary by non-authorized persons, an authorized employee, designated by the registrant in writing, must observe the area.

The Drug Control Unit has to be notified of any theft or loss of controlled substances. The registrant has to fill out and submit DDC-52 form or a DEA Form 106 in this case. An incident report has to be made. Public Safety and EHS will need to investigate record keeping and all practices.

#### Disposal

Controlled substances cannot be shared among laboratories and have to be handled only by registered users for the specific approved usage. All left over quantities and expired substances have to be accounted for.

Loss or discrepancy in the inventory has to be reported to the Public Safety and EHS office. A DEA Loss Form 106 might have to be filed depending on the quantity, substance, and circumstances of that loss. NJIT has the right to request record keeping and other relevant documents pertinent to such incident.

In case of disposal, the person in possession of CDS could contact the Special Agent in Charge from DEA for assistance. A DEA Form 41 shall be filled out by the registerant and 3 copies need to be sent to the Special Agent in Charge.

If the person in possession of the CDS is not a registrant, they need to provide the Special Agent in Charge with the name, address, quantity of each substance, and how the substance was obtained. The applicant has to provide the name, address, and registration number of the person who was in possession of the substance prior to the applicant, if that information is available.

The instructions for the disposal of the controlled substance will be provided by the Special Agent in Charge. EHS department can provide suggestions for registrants and individuals. If the disposal happens regularly, the registrant(s) might be able to follow the instructions provided by the Special Agent in Charge without being required to gain approval for each disposal.

The destruction will have to be documented on the usage log.



Department of **Environmental Health** & Safety

Contact Details:

http://www.njit.edu/environmentalsafety/

🗘 (973) 596-3059 🖄 healthandsafety@njit.edu

# **Controlled Substances Inspection Checklist**

#### **Laboratory Specifications:**

Principal investigator or Lab manager:	Phone:
Department:	Room:
Storage location/room#:	
Security arrangement:	
Persons present for inspection:	Date of Inspection:/

#### **Controlled Substances (CS) Use and Security:**

Sr.	Yes	No	N/A	Property
No.				
1				All users have completed background check and a statement to that effect is in the EH&S file
2				Entrance door is labeled with the name and phone numbers of the PI/Lab Manager.
3				The stocks of CS are stored in a locked secure facility
4				Prepared solutions of CS are stored and secured against theft/misuse
5				Access to the CS is restricted at all times to only those individuals who are listed on the current Authorization Form on file with the CSSO
6				Locks and/or safe combinations have been rekeyed/changed whenever personnel changes have occurred
7				All CS are stored according to their labeled instructions
8				All flip-off tops or other types of seals are intact on those items that have not yet been used
9				Receipts/original invoices of the CS have been filed
10				Separate records of Schedule I and II CS have been maintained from schedule III, IV and V CS
11				CS have not been loaned or shared with other laboratories or individuals not otherwise authorized to receive them nor transferred to other accounts
12				Inventory is kept for the receipt/use of Forms 222 used for purchase of schedule I and II CS
13				Photo copy of the order/receipt record received Semi-annually
14				Disposal of any expired materials or empty containers have been via proper channel
15				Records of any material disposed have been maintained and a copy provided to EH&S
16				The Controlled Substance Disposition Record (CSDR) is completed and current
17				Details of the use of the CS have been documented
18				A new and/or completed CSDR has been submitted within the last 12 months
19				Unavoidable loss (material sticking to the hypodermic needle or to the syringe) has been accounted for
20				A CS Authorization Update has been submitted to EH&S each time an addition or deletion from the list of authorization personnel has been made
21				All CSDR's are accurate and current; they account for the quantity utilized for each use and /or any waste or damaged materials
22				The perpetual balance on the CSDR accurately matches the quantity on hand stated in the Biennial Controlled Substances Inventory Form
23				All losses or discrepancies in recordkeeping have been promptly reported to EH&S upon discovery

4				The CSDR(s) form(s) include information about of the controlled substance(S) and the names of	·
				experiment	
5				The area users are aware of the administrative controlled substances, as outlined by the use of the search and Instruction at FIU	
6				A copy of the FIU CS Safety Manual is on file in	the research area
<del>7</del>				Standard Operating Procedures (SOP) and safe	
				CS and documented	ty gardennes are developed for disc of
Co	omme	nts:			
Н	ow an	d whe	en defi	ciencies were corrected:	
_					
Re	ecomr	nende	ed Acti	on from PI:	
	No ac	tion r	equire	d	
	Please	e resp	ond by	regarding implementation statu	is of the recommended measures
In	specte	ed By	:	Signature:	Date://



Page of

# **Biennial Controlled Substances Inventory**

The DEA requires a physical inventory of all controlled substances to be conducted every two years for each registered location. The inventory may be taken on any date within two years of the previous inventory date. The inventory Form must be kept at least for an additional two years at the registered site after completion.

Date:					Opening	of Business $\square$		Close of Business $\square$	
Registrant:									
Registrant Addre	ss:								
<b>DEA Registration</b>	#:								
Reference: 21 CFR	1304.04 &	21 CFI	R 1304.11 Inventory	Requirements					
Controlled Substance Name	DEA Schedule <sup>1,</sup> 2	10	ngth/Dosage form (e.g. 0 mg tablet, \10mg entration per ml etc)	# of units or vo each finished for Container (e.g. bottle or 3 m	orm per 100 tab	# of containers (e.g. four 100 tab bottles or six 3 ml vials)	disp whethe	substance is not in use (e.g. awaiti osal, defective etc) list reason an er substance is capable of use in mi ontrolled substance in finished forn	d fg of
an estimated cour	it or measure of	f the con		olds more than 1000	tablets or ca	psules in which case ma	ake an exa	bstance is listed in Schedule III, IV or V, ct count of the contents (CFR 1304.11(rrds (CFR 1304.04(g))	
			Name	!	Signature			Date	
Inventory perfori									
Inventory witnes	sed by:								

# **CONTROLLED SUBSTANCES**

# - ALPHABETICAL ORDER -

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
6-bromo-androsta-1,4-diene-3,17-dione	4000	Ш	N	
[3,2-c]-furazan-5α-androstan-17β-ol	4000	III	N	
[3,2-c]pyrazole-androst-4-en-17β-ol	4000	III	N	
1-(1-Phenylcyclohexyl)pyrrolidine	7458	I	N	PCPy, PHP, rolicyclidine
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine	9663	I	Υ	PEPAP, synthetic heroin
1-[1-(2-Thienyl)cyclohexyl]piperidine	7470	- 1	N	TCP, tenocyclidine
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine	7473	I	N	ТСРу
13Beta-ethyl-17beta-hydroxygon-4-en-3-one	4000	III	N	
17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha- androstane	4000	III	N	
17Alpha-methyl-3beta,17beta-dihydroxy-5alpha- androstane	4000	III	N	
17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene	4000	III	N	
17Alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one)	4000	III	N	
17Alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one)	4000	III	N	17-Alpha-methyl-1-testosterone
17α-Methyl-5α-androstan-17β-ol	4000	III	N	
17α-methyl-androst-2-ene-3,17β-diol	4000	III	N	
17α-methyl-androsta-1,4-diene-3,17β-diol	4000	III	N	
17α-Methyl-androstan-3-hydroxyimine-17β-ol	4000	III	N	
17β-Hydroxy-androstano[2,3-d]isoxazole	4000	III	N	
17β-Hydroxy-androstano[3,2-c]isoxazole	4000	III	N	
18a-Homo-3-hydroxy-estra-2,5(10)-dien-17-one	4000	III	N	
19-Nor-4,9(10)-androstadienedione	4000	III	N	
19-Nor-4-androstenediol (3beta,17beta-dihydroxyestr-4 ene; 3alpha,17beta-dihydroxyestr-4-ene)	4000	III	N	
19-Nor-4-androstenedione (estr-4-en-3,17-dione)	4000	III	N	
19-Nor-5-androstenediol (3beta,17beta-dihydroxyestr-5 ene; 3alpha,17beta-dihydroxyestr-5-ene)	4000	III	N	
19-Nor-5-androstenedione (estr-5-en-3,17-dione)	4000	III	N	
1-Androstenediol (3beta,17beta-dihydroxy-5alpha- androst-1-ene; 3alpha,17beta-dihydroxy-5alpha- androst-1-ene)	4000	III	N	
1-Androstenedione (5alpha-androst-1-en-3,17-dione)	4000	III	N	
1-Methyl-4-phenyl-4-propionoxypiperidine	9661	I	Υ	MPPP, synthetic heroin

	DEA	CSA		
SUBSTANCE	NUMBER	SCH	NARC	OTHER NAMES
1-Phenylcyclohexylamine	7460	II	N	PCP precursor
1-Piperidinocyclohexanecarbonitrile	8603	II	N	PCC, PCP precursor
2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C-P)	7524	I	N	2C-P
2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E)	7509	1	N	2C-E (Positional Isomer: 2,5-Dimethoxy-3,4-dimethylphenethylamine (2C-G))
2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C-D)	7508	I	N	2C-D
2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N)	7521	1	N	2C-N
2-(2,5-Dimethoxyphenyl) ethanamine (2C-H)	7517	I	N	2C-H
2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B-NBOMe)	7536	I	N	25B-NBOMe, 2C-B-NBOMe, 25B, Cimbi-36
2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C)	7519	I	N	2C-C
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe)	7537	I	N	25C-NBOMe, 2C-C-NBOMe, 25C, Cimbi-82
2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C-T-2)	7385	I	N	2C-T-2
2-(4-iodo-2,5-dimethoxyphenyl) ethanamine (2C-I)	7518	I	N	2C-I
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe)	7538	I	N	25I-NBOMe, 2C-I-NBOMe, 25I, Cimbi-5
2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine (2C-T-4)	7532	I	N	2C-T-4 (Positional Isomer: 2,5-Dimethoxy-4-ethylthioamphetamine (Aleph-2))
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)	7348	I	N	2C-T-7 (Positional Isomer: 2,5-Dimethoxy-4-ethylthioamphetamine (Aleph-2))
2,5-Dimethoxy-4-ethylamphetamine	7399	I	N	DOET
2,5-Dimethoxyamphetamine	7396	I	N	DMA, 2,5-DMA
2-methoxy-N-(1-phenethylpiperidin-4-yl)-N- ohenylacetamide	9825	I	Υ	Methoxyacetyl fentanyl
2α,17α-dimethyl-17β-hydroxy-5β-androstan-3-one	4000	III	N	
2α,3α-epithio-17α-methyl-5α-androstan-17β-ol	4000	III	N	
3,4,5-Trimethoxyamphetamine	7390	I	N	TMA (Positional Isomers: 2,4,5-Trimethoxy- amphetamine (TMA-5), 2,4,6-Trimethoxy- amphetamine (TMA-6), Escaline)
3,4-Methylenedioxyamphetamine	7400	1	N	MDA, Love Drug
3,4-Methylenedioxymethamphetamine	7405	I	N	MDMA, Ecstasy, XTC
3,4-Methylenedioxy-N-ethylamphetamine	7404	I	N	N-ethyl MDA, MDE, MDEA
3Alpha,17beta-dihydroxy-5alpha-androstane	4000	III	N	
3Beta,17beta-dihydroxy-5alpha-androstane	4000	III	N	
3-Fluoro-N-methylcathinone (3-FMC)	1233	I	N	1-(3-fluorophenyl)-2-(methylamino)propan-1-one) (Positional isomer: 2-FMC)
3-Methylfentanyl	9813	I	Υ	China White, fentanyl
3-Methylthiofentanyl	9833	I	Υ	China White, fentanyl
3β-hydroxy-estra-4,9,11-trien-17-one	4000	III	N	

	DEA	CSA		
SUBSTANCE	NUMBER	SCH	NARC	OTHER NAMES
4-Androstenediol (3beta,17beta-dihydroxy-androst-4- ene)	4000	III	N	4-AD
4-Androstenedione (androst-4-en-3,17-dione)	4000	III	N	
4-Anilino-N-phenethyl-4-piperidine (ANPP)	8333	II	N	ANPP, Despropionyl fentanyl
4-Bromo-2,5-dimethoxyamphetamine	7391	- 1	N	DOB, 4-bromo-DMA
4-Bromo-2,5-dimethoxyphenethylamine	7392	I	N	2C-B, Nexus, has been sold as Ecstasy, i.e. MDMA
4-chloro-17α-methyl-17β-hydroxy-androst-4-en-3-one	4000	III	N	
4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11- dione	4000	III	N	
4-chloro-17α-methyl-androst-4-ene-3β,17β-diol	4000	III	N	
4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol	4000	III	N	
4-CN-CUMYL-BUTINACA (1-(4-cyanobutyl)-N-(2- ohenylpropan-2-yl)-1 H-indazole-3-carboxamide)	7089	I	N	4-cyano-CUMYL-BUTINACA; 4-CN-CUMYL BINACA; CUMYL-4CN-BINACA; SGT-78
4-Dihydrotestosterone (17beta-hydroxyandrostan-3- one)	4000	III	N	Anabolex, Andractim, Pesomax, Stanolone
4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)isobutyramide)	9824	1	Υ	Para-fluoroisobutyryl fentanyl
4-Fluoro-N-methylcathinone (4-FMC)	1238	I	N	flephedrone; 1-(4-fluorophenyl)-2- (methylamino)propan-1-one) (Positional isomer: 2- FMC)
4-Hydroxy-19-nortestosterone (4,17beta-dihydroxyestr- 4-en-3-one)	4000	III	N	
4-Hydroxy-androst-4-ene-3,17-dione	4000	III	N	Listed as 4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5 $\alpha$ -androstan-17 $\beta$ -ol
4-Hydroxytestosterone (4,17beta-dihydroxyandrost-4- en-3-one)	4000	III	N	
4-Methoxyamphetamine	7411	I	N	PMA
4-Methyl-2,5-dimethoxyamphetamine	7395	I	N	DOM, STP (Positional Isomer: 2,5-Dimethoxy-3,4-dimethylphenethylamine (2C-G))
4-Methyl-alphapyrrolidinopropiophenone (4-MePPP)	7498	I	N	MePPP, 4-methyl- $\alpha$ -pyrrolidinopropiophenone, 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)-propan-1-one)
4-Methylaminorex (cis isomer)	1590	I	N	U4Euh, McN-422
4-Methyl-N-ethylcathinone (4-MEC)	1249	I	N	2-(ethylamino)-1-(4-methylphenyl)propan-1- one)(Positional Isomers:3-methylethcathinone (3- MEC), 4-ethylmethcathinone (4-EMC), 4- methylbuphedrone (4-MeMABP;4-MeBP), 3,4- dimethylmethcathinone(3,4-DMMC),N- ethylbuphedrone (NEB),N-ethyl-N- methylcathinone(EMC))
5-Androstenediol (3beta,17beta-dihydroxy-androst-5- ene)	4000	III	N	
5-Androstenedione (androst-5-en-3,17-dione)	4000	III	N	
5F-AB-PINACA (N-(1-amino-3-methyl-1-oxobutan-2-	7025	I	N	

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
5F–ADB; 5F–MDMB–PINACA (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)	7034	ı	N	5F-ADB, 5F-MDMB-PINACA
5F–AMB (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate)	7033	I	N	5F-AMB
5F–APINACA, 5F–AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide)	7049	I	N	5F-APINACA, 5F-AKB48
5F-CUMYL-P7AICA (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1 H-pyrrolo[2,3-b]pyridine-3-carboxamide)	7085	I	N	
5-Fluoro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone	7011	I	N	5-Fluoro-UR-144, XLR-11 and XLR11
5F-PB-22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate)	7225	I	N	5-Fluoro-PB-22; 5F-PB-22
5-Methoxy-3,4-methylenedioxyamphetamine	7401	I	N	MMDA
5-Methoxy-N,N-diisopropyltryptamine	7439	- 1	N	5-MeO-DIPT (Positional Isomer: 5-Methoxy-N,N-dipropyltryptamine (5-MeO-DPT))
5-Methoxy-N-N-dimethyltryptamine	7431	I	N	5-MeO-DMT (Positional Isomer: 4-Methoxy-N,N-dimethyltryptamine (4-MeO-DMT))
5α-Androstan-3,6,17-trione	4000	III	N	
6-bromo-androstan-3,17-dione	4000	III	N	
6α-Methyl-androst-4-ene-3,17-dione	4000	III	N	
AB-CHMINACA (N-(1-amino-3-methyl-1- oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide	7031	I	N	AB-CHMINACA
AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)	7012	I	N	AB-FUBINACA
AB-PINACA (N-(1-amino-3-methyl- 1-oxobutan-2-yl)-1-pentyl-1H-indazole- 3-carboxamide)	7023	I	N	AB-PINACA
Acetorphine	9319	- 1	Υ	
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylacetamide)	9821	I	Υ	
Acetyl-alpha-methylfentanyl	9815	I	Υ	
Acetyldihydrocodeine	9051	I	Υ	Acetylcodone
Acetylmethadol	9601	I	Υ	Methadyl acetate
Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylacrylamide)	9811	I	Υ	Acryloylfentanyl
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)	7010	I	N	ADB-FUBINACA
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide)	7035	I	N	ADB-PINACA
AH-7921 (3,4-dichloro-N-[(1-dimethyl]benzamide))	9551	I	Υ	AH-7921
Alfaxalone	2731	IV	N	Alfaxan, 5α-pregnan-3α-ol-11,20-dione
Alfentanil	9737	П	Υ	Alfenta

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Allylprodine	9602	I	Υ	
Alphacetylmethadol except levo-alphacetylmethadol	9603	1	Υ	
Alpha-ethyltryptamine	7249	I	N	ET, Trip
Alphameprodine	9604	I	Υ	
Alphamethadol	9605	I	Υ	
Alpha-methylfentanyl	9814	I	Υ	China White, fentanyl
Alpha-methylthiofentanyl	9832	I	Υ	China White, fentanyl
Alpha-methyltryptamine	7432	I	N	AMT (Positional Isomer: N-Methyltryptamine)
Alphaprodine	9010	Ш	Υ	Nisentil
alpha-pyrrolidinobutiophenone (α-PBP)	7546	I	N	1-phenyl-2-(pyrrolidin-1-yl)butan-1-one)
alpha-pyrrolidinopentiophenone (α-PVP)	7545	I	N	α-pyrrolidinovalerophenone, 1-phenyl-2- (pyrrolidin-1-yl)pentan-1-one)(Positional isomers: 4-methyl-α-pyrrolidinobutiophenone (4-MePBP), 1-phenyl-2-(piperidin-1-yl)butan-1-one)
Alprazolam	2882	IV	N	Xanax
AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole)	7201	I	N	AM2201
AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole)	7694	I	N	AM-694
Aminorex	1585	I	N	has been sold as methamphetamine
Amobarbital	2125	Ш	N	Amytal, Tuinal
Amobarbital & noncontrolled active ingred.	2126	III	N	
Amobarbital suppository dosage form	2126	III	N	
Amphetamine	1100	II	N	Dexedrine, Adderall, Obetrol
Anabolic steroids	4000	III	N	"Body Building" drugs
Androstanedione (5alpha-androstan-3,17-dione)	4000	III	N	
Anileridine	9020	Ш	Υ	Leritine
APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide	7048	I	N	APINACA and AKB48
Approved Cannabidiol Drugs (as defined in 21 CFR 1308.15(f))	7367	V	N	A drug product in finished dosage formulation that has been approved by the U.S. Food and Drug Administration that contains Cannabidiol derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
Aprobarbital	2100	III	N	Alurate
Barbital	2145	IV	N	Veronal, Plexonal, barbitone
Barbituric acid derivative	2100	III	N	Barbiturates not specifically listed
Benzethidine	9606	- 1	Υ	
Benzphetamine	1228	III	N	Didrex, Inapetyl
Benzylmorphine	9052	1	Υ	
Betacetylmethadol	9607	I	Υ	
Beta-hydroxy-3-methylfentanyl	9831	I	Υ	China White, fentanyl

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Beta-hydroxyfentanyl	9830	I	Y	China White, fentanyl
Beta-hydroxythiofentanyl	9836	I	Y	N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]- N-phenylpropionamide, N-[1-[2-hydroxy-2-(2- thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide
Betameprodine	9608	I	Υ	
Betamethadol	9609	I	Υ	
Betaprodine	9611	I	Υ	
Bezitramide	9800	II	Υ	Burgodin
Bolasterone (7alpha,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one)	4000	III	N	
Boldenone (17beta-hydroxyandrost-1,4-diene-3-one)	4000	III	N	Equipoise, Parenabol, Vebonol, dehydrotestosterone
Boldione	4000	III	N	
Brivaracetam	2710	V	N	BRV, UCB-34714, Briviact, ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide)
Bromazepam	2748	IV	N	Lexotan, Lexatin, Lexotanil
Bufotenine	7433	I	N	Mappine, N,N-dimethylserotonin
Buprenorphine	9064	Ш	Υ	Buprenex, Temgesic, Subutex, Suboxone
Butabarbital (secbutabarbital)	2100	III	N	Butisol, Butibel
Butalbital	2100	III	N	Fiorinal, Butalbital with aspirin
Butobarbital (butethal)	2100	III	N	Soneryl (UK)
Butorphanol	9720	IV	N	Stadol, Stadol NS, Torbugesic, Torbutrol
Butylone	7541	I	N	bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2- (methylamino)butan-1-one) (Positional Isomers: ethylone (bk-MDEA; MDEC), dimethylone (bk- MDDMA; MDDMC))
Butyryl Fentanyl	9822	I	Υ	N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide
Calusterone (7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one)	4000	III	N	Methosarb
Camazepam	2749	IV	N	Albego, Limpidon, Paxor
Carfentanil	9743	Ш	Υ	Wildnil
Carisoprodol	8192	IV	N	Soma
Cathine	1230	IV	N	Constituent of "Khat" plant, (+)-norpseudoephedrine
Cathinone	1235	I	N	Constituent of "Khat" plant
Chloral betaine	2460	IV	N	Beta Chlor
Chloral hydrate	2465	IV	N	Noctec
Chlordiazepoxide	2744	IV	N	Librium, Libritabs, Limbitrol, SK-Lygen
Chlorhexadol	2510	III	N	Mechloral, Mecoral, Medodorm, Chloralodol
Chlorphentermine	1645	III	N	Pre-Sate, Lucofen, Apsedon, Desopimon
Clobazam	2751	IV	N	Urbadan, Urbanyl
Clonazepam	2737	IV	N	Klonopin, Clonopin

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Clonitazene	9612	I	Y	
Clorazepate	2768	IV	N	Tranxene
Clortermine	1647	III	N	Voranil
Clostebol (4-chloro-17beta-hydroxyandrost-4-en-3-one)	4000	III	N	Alfa-Trofodermin, Clostene, 4-chlorotestosterone
Clotiazepam	2752	IV	N	Trecalmo, Rize, Clozan, Veratran
Cloxazolam	2753	IV	N	Akton, Lubalix, Olcadil, Sepazon
Coca Leaves	9040	П	Υ	
Cocaine	9041	П	Υ	Methyl benzoylecgonine, Crack
Codeine	9050	П	Υ	Morphine methyl ester, methyl morphine
Codeine & isoquinoline alkaloid 90 mg/du	9803	III	Υ	Codeine with papaverine or noscapine
Codeine combination product 90 mg/du	9804	III	Υ	Empirin,Fiorinal,Tylenol,ASA or APAP w/codeine
Codeine methylbromide	9070	- 1	Υ	
Codeine preparations - 200 mg/(100 ml or 100 gm)		V	Υ	Cosanyl,Robitussin A-C,Cheracol,Cerose,Pediacof
Codeine-N-oxide	9053	I	Υ	
CP-47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-nydroxycyclohexyl-phenol)	7297	I	N	CP-47,497
CP-47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2- ((1R,3S)3-hydroxycyclohexyl-phenol)	7298	I	N	CP-47,497 C8 Homologue
Cyclopentyl fentanyl	9847	I	Υ	N-(1-phenethylpiperidin-4-yl)-N- phenylcyclopentanecarboxamide
Cyclopropyl Fentanyl	9845	I	Υ	N-(1-phenethylpiperidin-4-yl)-N- phenylcyclopropanecarboxamide
Cyprenorphine	9054	I	Υ	
Dehydrochloromethyltestosterone (4-chloro-17beta- nydroxy-17alpha-methylandrost-1,4-dien-3-one)	4000	III	N	Oral-Turinabol
Delorazepam	2754	IV	N	
Delta1-dihydrotestosterone (17beta-hydroxy-5alpha- androst-1-en-3-one)	4000	III	N	1-Testosterone
Desomorphine	9055	I	Υ	
Desoxymethyltestosterone	4000	III	N	
Dexfenfluramine	1670	IV	N	Redux
Dextromoramide	9613	ı	Υ	Palfium, Jetrium, Narcolo
Dextropropoxyphene dosage forms	9278	IV	Υ	Darvon, propoxyphene, Darvocet, Propacet
Dextropropoxyphene, bulk (non-dosage forms)	9273	II	Υ	Propoxyphene
Diampromide	9615	I	Υ	
Diazepam	2765	IV	N	Valium, Diastat
Dichloralphenazone	2467	IV	N	Midrin, dichloralantipyrine
•				

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Diethyltryptamine	7434	I	N	DET, N,N-Diethyltryptamine (Positional Isomer: N-Methyl-N-isopropyltryptamine (MiPT))
Difenoxin	9168	I	Υ	Lyspafen
Difenoxin 1 mg/25 ug AtSO4/du	9167	IV	Υ	Motofen
Difenoxin preparations - 0.5 mg/25 ug AtSO4/du		V	Υ	Motofen
Dihydrocodeine	9120	II	Υ	Didrate, Parzone
Dihydrocodeine combination product 90 mg/du	9807	III	Υ	Synalgos-DC, Compal
Dihydrocodeine preparations 100mg/(100 ml or 100 gm)		V	Υ	Cophene-S, various others
Dihydroetorphine	9334	П	Υ	DHE
Dihydromorphine	9145	I	Υ	
Dimenoxadol	9617	I	Υ	
Dimepheptanol	9618	- 1	Υ	
Dimethylthiambutene	9619	I	Y	
Dimethyltryptamine	7435	1	N	DMT
Dioxaphetyl butyrate	9621	ı	Υ	
Diphenoxylate	9170	Ш	Υ	
Diphenoxylate preparations 2.5 mg/25 ug AtSO4		V	Υ	Lomotil, Logen
Dipipanone	9622	- 1	Υ	Dipipan, phenylpiperone HCl, Diconal, Wellconal
Dronabinol (synthetic) in sesame oil in soft gelatin capsule as approved by FDA	7369	III	N	Marinol, synthetic THC in sesame oil/soft gelatin as approved by FDA
Dronabinol in an oral solution in a drug product approved for marketing by the U.S. Food and Drug Administration	7365	II	N	Syndros
Drostanolone (17beta-hydroxy-2alpha-methyl-5alpha- androstan-3-one)	4000	III	N	Drolban, Masterid, Permastril
Drotebanol	9335	I	Υ	Metebanyl, oxymethebanol
Ecgonine	9180	II	Υ	Cocaine precursor, in Coca leaves
Eluxadoline	9725	IV	N	VIBERZI
Embutramide	2020	III	N	Tributane
Estazolam	2756	IV	N	ProSom, Domnamid, Eurodin, Nuctalon
Estra-4,9,11-triene-3,17-dione	4000	III	N	
Ethchlorvynol	2540	IV	N	Placidyl
Ethinamate	2545	IV	N	Valmid, Valamin
Ethyl loflazepate	2758	IV	N	
Ethylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene)	4000	III	N	Maxibolin, Orabolin, Durabolin-O, Duraboral
Ethylmethylthiambutene	9623	- 1	Υ	
Ethylmorphine	9190	II	Υ	Dionin
Ethylmorphine combination product 15 mg/du	9808	III	Υ	

	DEA	CSA		
SUBSTANCE	NUMBER	SCH	NARC	OTHER NAMES
Ethylmorphine preparations 100 mg/(100 ml or 100 gm	)	V	Y	
Etonitazene	9624	I	Υ	
Etorphine (except HCI)	9056	I	Υ	
Etorphine HCI	9059	II	Υ	M 99
Etoxeridine	9625	I	Υ	
Ezogabine	2779	V	N	Potiga
Fencamfamin	1760	IV	N	Reactivan
Fenethylline	1503	1	N	Captagon,amfetyline,ethyltheophylline amphetamine
Fenfluramine	1670	IV	N	Pondimin, Ponderal
Fenproporex	1575	IV	N	Gacilin, Solvolip
Fentanyl	9801	II	Υ	Duragesic, Oralet, Actiq, Sublimaze, Innovar
Fentanyl related-compounds as defined in 21 CFR 1308.11(h)	9850	1	Υ	
Fludiazepam	2759	IV	N	
Flunitrazepam	2763	IV	N	Rohypnol, Narcozep, Darkene, Roipnol
Fluoxymesterone (9-fluoro-17alpha-methyl- 11beta,17beta-dihydroxyandrost-4-en-3-one)	4000	III	N	Anadroid-F, Halotestin, Ora-Testryl
Flurazepam	2767	IV	N	Dalmane
Formebolone (2-formyl-17alpha-methyl- 11alpha,17beta-dihydroxyandrost-1,4-dien-3-one)	4000	III	N	Esiclene, Hubernol
Fospropofol	2138	IV	N	Lusedra
Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylfuran-2-carboxamide)	9834	I	Υ	
Furazabol (17alpha-methyl-17beta- hydroxyandrostano[2,3-c]-furazan)	4000	III	N	Frazalon, Miotolon, Qu Zhi Shu
Furethidine	9626	I	Y	
Gamma Hydroxybutyric Acid	2010	1	N	GHB, gamma hydroxybutyrate, sodium oxybate
Gamma Hydroxybutyric Acid preparations	2012	III	N	Xyrem
Glutethimide	2550	II	N	Doriden, Dorimide
Halazepam	2762	IV	N	Paxipam
Haloxazolam	2771	IV	N	
Heroin	9200	I	Υ	Diacetylmorphine, diamorphine
Hydrocodone	9193	II	Υ	dihydrocodeinone
Hydromorphinol	9301	I	Υ	
Hydromorphone	9150	II	Υ	Dilaudid, dihydromorphinone
Hydroxypethidine	9627	I	Y	
Ibogaine	7260	1	N	Constituent of "Tabernanthe iboga" plant
Isobutyryl fentanyl	9827	I	Υ	N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide
Isomethadone	9226	II	Υ	Isoamidone

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole)	7118	I	N	JWH-018 and AM-678
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole)	7019	- 1	N	JWH-019
JWH-073 (1-Butyl-3-(1-naphthoyl)indole)	7173	ı	N	JWH-073
JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole)	7081	I	N	JWH-081
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole)	7122	I	N	JWH-122
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole)	7200	I	N	JWH-200
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole)	7203	I	N	JWH-203
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole)	6250	- 1	N	JWH-250
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole)	7398	ı	N	JWH-398
Ketamine	7285	III	N	Ketaset, Ketalar, Special K, K
Ketazolam	2772	IV	N	Anxon, Loftran, Solatran, Contamex
Ketobemidone	9628	I	Υ	Cliradon
Lacosamide	2746	V	N	Vimpat
Levo-alphacetylmethadol	9648	II	Υ	LAAM, long acting methadone, levomethadyl acetate
Levomethorphan	9210	II	Υ	
Levomoramide	9629	I	Υ	
Levophenacylmorphan	9631	ı	Υ	
Levorphanol	9220	II	Υ	Levo-Dromoran
Lisdexamfetamine	1205	II	N	Vyvanse
Loprazolam	2773	IV	N	
Lorazepam	2885	IV	N	Ativan
Lorcaserin	1625	IV	N	Belviq
Lormetazepam	2774	IV	N	Noctamid
Lysergic acid	7300	III	N	LSD precursor
Lysergic acid amide	7310	III	N	LSD precursor
Lysergic acid diethylamide	7315	- 1	N	LSD, lysergide
MAB-CHMINACA (N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide)	7032	I	N	MAB-CHMINACA and ADB-CHMINACA
Marihuana	7360	1	N	Cannabis, marijuana
Marihuana Extract	7350	I	N	
Mazindol	1605	IV	N	Sanorex, Mazanor
MDMB–CHMICA, MMB–CHMINACA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate)	7042	I	N	MDMB-CHMICA, MMB-CHMINACA
MDMB–FUBINACA (Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)	7020	1	N	MDMB-FUBINACA
MDPV (3,4-Methylenedioxypyrovalerone)	7535	I	N	MDPV

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Mebutamate	2800	IV	N	Capla
Mecloqualone	2572	I	N	Nubarene
Medazepam	2836	IV	N	Nobrium
Mefenorex	1580	IV	N	Anorexic, Amexate, Doracil, Pondinil
Meperidine	9230	II	Υ	Demerol, Mepergan, pethidine
Meperidine intermediate-A	9232	II	Υ	Meperidine precursor
Meperidine intermediate-B	9233	Ш	Υ	Meperidine precursor, normeperidine
Meperidine intermediate-C	9234	II	Υ	Meperidine precursor
Mephedrone (4-Methyl-N-methylcathinone)	1248	I	N	(Positional Isomers: 3-Methyl-methcathinone, Buphedrone, Ethcathinone, N,N-Dimethyl-cathinone
Meprobamate	2820	IV	N	Miltown, Equanil, Micrainin, Equagesic, Meprospan
Mescaline	7381	I	N	Constituent of "Peyote" cacti
Mestanolone (17alpha-methyl-17beta-hydroxy-5alpha- androstan-3-one)	4000	III	N	Assimil, Ermalone, Methybol, Tantarone
Mesterolone (1alpha-methyl-17beta-hydroxy-5alpha- androstan-3-one)	4000	III	N	Androviron, Proviron, Testiwop
Metazocine	9240	II	Υ	
Methadone	9250	II	Υ	Dolophine, Methadose, Amidone
Methadone intermediate	9254	II	Υ	Methadone precursor
Methamphetamine	1105	II	N	Desoxyn, D-desoxyephedrine, ICE, Crank, Speed
Methandienone (17alpha-methyl-17beta- hydroxyandrost-1,4-dien-3-one)	4000	III	N	Dianabol, Metabolina, Nerobol, Perbolin
Methandriol (17alpha-methyl-3beta,17beta- dihydroxyandrost-5-ene)	4000	III	N	Sinesex, Stenediol, Troformone
Methaqualone	2565	I	N	Quaalude, Parest, Somnafac, Opitimil, Mandrax
Methasterone (2alpha,17alpha-dimethyl-5alpha- androstan-17beta-ol-3-one)	4000	III	N	Methasterone; $2\alpha,17\alpha$ -dimethyl-17 $\beta$ -hydroxy-5 $\alpha$ -androstan-3-one
Methcathinone	1237	I	N	N-Methylcathinone, "cat"
Methenolone (1-methyl-17beta-hydroxy-5alpha-androst 1-en-3-one)	4000	III	N	Primobolan, Primobolan Depot, Primobolan S
Methohexital	2264	IV	N	Brevital
Methyl 2-(1-(4-fluorobenzyl)-1Hindazole-3- carboxamido)-3- methylbutanoate	7021	I	N	FUB-AMB, MMB- FUBINACA, AMB-FUBINACA
Methyldesorphine	9302	I	Υ	
Methyldienolone (17alpha-methyl-17beta-hydroxyestra- 4,9(10)-dien-3-one)	4000	III	N	
Methyldihydromorphine	9304	I	Υ	
Methylone (3,4-Methylenedioxy-N-methylcathinone)	7540	I	N	(Positional Isomer: 2,3-methylenedioxymethcathinone (2,3-MDMC, 1-(benzo[d][1,3]dioxol-4-yl)-2-(methylamino)propan-1-one))
Methylphenidate	1724	II	N	Concerta, Ritalin, Methylin

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Methylphenobarbital (mephobarbital)	2250	IV	N	Mebaral, mephobarbital
Methyltestosterone (17alpha-methyl-17beta- hydroxyandrost-4-en-3-one)	4000	III	N	Android, Oreton, Testred, Virilon
Methyltrienolone (17alpha-methyl-17beta-hydroxyestra- 4,9,11-trien-3-one)	4000	III	N	Metribolone
Methyprylon	2575	III	N	Noludar
Metopon	9260	II	Υ	
Mibolerone (7alpha,17alpha-dimethyl-17beta- hydroxyestr-4-en-3-one)	4000	III	N	Cheque, Matenon
Midazolam	2884	IV	N	Versed
MMB-CHMICA, AMB-CHMICA (methyl 2-(1- (cyclohexylmethyl)-1 H-indole-3-carboxamido)-3- methylbutanoate)	7044	I	N	
Modafinil	1680	IV	N	Provigil
Moramide-intermediate	9802	II	Υ	
Morpheridine	9632	1	Υ	
Morphine	9300	II	Υ	MS Contin, Roxanol, Oramorph, RMS, MSIR
Morphine combination product/50 mg/(100 ml or 100 gm)	9810	III	Y	
Morphine methylbromide	9305	I	Υ	
Morphine methylsulfonate	9306	1	Υ	
Morphine-N-oxide	9307	I	Υ	
MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine))	9560	1	Υ	MT-45
Myrophine	9308	I	Υ	
N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran- 2-carboxamide	9843	I	Y	Tetrahydrofuranyl fentanyl
N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4- yl)propionamide	9816	I	Y	Ortho-fluorofentanyl or 2-fluorofentanyl
N,N-Dimethylamphetamine	1480	1	N	
Nabilone	7379	II	N	Cesamet
Nalorphine	9400	III	Υ	Nalline
Nandrolone (17beta-hydroxyestr-4-en-3-one)	4000	Ш	N	Deca-Durabolin, Durabolin, Durabolin-50
Naphyrone	1258	I	N	naphthylpyrovalerone; 1-(naphthalen-2-yl)-2- (pyrrolidin-1-yl)pentan-1-one) (Positional Isomer: $\alpha$ -naphyrone)
N-Benzylpiperazine	7493	Ī	N	BZP, 1-benzylpiperazine
N-Ethyl-1-phenylcyclohexylamine	7455	I	N	PCE
N-Ethyl-3-piperidyl benzilate	7482	I	N	JB 323
N-Ethylamphetamine	1475	I	N	NEA
N-Ethylpentylone (1-(1,3-benzodioxol-5-yl)-2- (ethylamino)-pentan-1-one)	7543	I	N	Ephylone
N-Hydroxy-3,4-methylenedioxyamphetamine	7402	- 1	N	N-hydroxy MDA

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Nicocodeine	9309	I	Υ	
Nicomorphine	9312	1	Υ	Vilan
Nimetazepam	2837	IV	N	Erimin
Nitrazepam	2834	IV	N	Mogadon
NM2201; CBL2201 (Naphthalen-1-yl 1-(5-fluoropentyl)- 1 H-indole-3-carboxylate)	7221	I	N	
N-Methyl-3-piperidyl benzilate	7484	I	N	JB 336
Noracymethadol	9633	I	Υ	
Norbolethone (13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one)	4000	III	N	Genabol
Norclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one	4000	III	N	Anabol-4-19, Lentabol
Nordiazepam	2838	IV	N	Nordazepam, Demadar, Madar
Norethandrolone (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one)	4000	III	N	Nilevar, Pronabol, Solevar
Norlevorphanol	9634	1	Y	
Normethadone	9635	I	Υ	Phenyldimazone
Normethandrolone (17alpha-methyl-17beta- hydroxyestr-4-en-3-one)	4000	III	N	Lutenin, Matronal, Orgasteron
Normorphine	9313	I	Υ	
Norpipanone	9636	1	Υ	
Ocfentanil	9838	I	Y	N-(2-fluorophenyl)-2-methoxy-N-(1- phenethylpiperidin-4-yl)acetamide
Opium combination product 25 mg/du	9809	III	Y	Paregoric, other combination products
Opium extracts	9610	II	Υ	
Opium fluid extract	9620	II	Υ	
Opium poppy	9650	II	Υ	Papaver somniferum
Opium preparations - 100 mg/(100 ml or 100 gm)		V	Υ	Parepectolin, Kapectolin PG, Kaolin Pectin P.G.
Opium tincture	9630	II	Υ	Laudanum
Opium, granulated	9640	II	Υ	Granulated opium
Opium, powdered	9639	II	Υ	Powdered opium
Opium, raw	9600	II	Υ	Raw opium, gum opium
Oripavine	9330	II	Υ	
Oxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa-5alpha-androstan-3-one)	4000	III	N	Anavar, Lonavar, Oxandrin, Provitar, Vasorome
Oxazepam	2835	IV	N	Serax, Serenid-D
Oxazolam	2839	IV	N	Serenal, Convertal
Oxycodone	9143	II	Υ	OxyContin, Percocet, Endocet, Roxicodone, Roxicet,
Oxymesterone (17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one)	4000	III	N	Anamidol, Balnimax, Oranabol, Oranabol 10

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Oxymetholone (17alpha-methyl-2-hydroxymethylene- 17beta-hydroxy-5alpha-androstan-3-one)	4000	III	N	Anadrol-50, Adroyd, Anapolon, Anasteron, Pardroyd
Oxymorphone	9652	II	Υ	Numorphan
Para-chloroisobutyryl fentanyl	9826	I	Υ	N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide
Para-fluorobutyryl fentanyl	9823	1	Υ	N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide
Para-Fluorofentanyl	9812	I	Υ	China White, fentanyl
Parahexyl	7374	I	N	Synhexyl,
Paraldehyde	2585	IV	N	Paral
Para-methoxybutyryl fentanyl	9837	I	Υ	N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide
PB-22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate)	7222	I	N	QUPIC; PB-22
Pemoline	1530	IV	N	Cylert
Pentazocine	9709	IV	N	Talwin, Talwin NX, Talacen, Talwin Compound
Pentedrone (α-methylaminovalerophenone)	1246	I	N	2-(methylamino)-1-phenylpentan-1-one)(Positional Isomers:3-methylethcathinone (3-MEC), 4-ethylmethcathinone (4-EMC), 4-methylbuphedrone (4-MeMABP;4-MeBP), 3,4-dimethylmethcathinone (3,4-DMMC),N-ethylbuphedrone (NEB),N-ethyl-N-methylcathinone(EMC))
Pentobarbital	2270	II	N	Nembutal
Pentobarbital & noncontrolled active ingred.	2271	III	N	FP-3
Pentobarbital suppository dosage form	2271	Ш	N	WANS
Pentylone	7542	I	N	bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2- (methylamino)pentan-1-one) (Positional Isomers: dibutylone (bk-DMBDB) and propylone (3',4'- methylenedioxy-N-propylaminocathinone, 1- (benzo[d][1,3]dioxol-5-yl)-2-(propylamino)propan-1- one))
Perampanel	2261	III	N	Fycompa, [2-(2-oxo-l-phenyl- 5-pyridin-2-yl-l ,2-dihydropyridin-3-yl) benzonitrile ]
Petrichloral	2591	IV	N	Pentaerythritol chloral, Periclor
Peyote	7415	I	N	Cactus which contains mescaline
Phenadoxone	9637	- 1	Υ	
Phenampromide	9638	1	Υ	
Phenazocine	9715	II	Υ	Narphen, Prinadol
Phencyclidine	7471	II	N	PCP, Sernylan
Phendimetrazine	1615	III	N	Plegine, Prelu-2, Bontril, Melfiat, Statobex
Phenmetrazine	1631	II	N	Preludin
Phenobarbital	2285	IV	N	Luminal, Bellergal-S
Phenomorphan	9647	I	Υ	
			Υ	

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Phentermine	1640	IV	N	Ionamin, Fastin, Adipex-P, Obe-Nix, Zantryl
Phenylacetone	8501	II	N	P2P, phenyl-2-propanone, benzyl methyl ketone
Pholcodine	9314	ı	Υ	Copholco, Adaphol, Codisol, Lantuss, Pholcolin
Piminodine	9730	II	Υ	
Pinazepam	2883	IV	N	Domar
Pipradrol	1750	IV	N	Detaril, Stimolag Fortis
Piritramide	9642	I	Υ	Piridolan
Poppy Straw	9650	Ш	Υ	Opium poppy capsules, poppy heads
Poppy Straw Concentrate	9670	П	Υ	Concentrate of Poppy Straw, CPS
Prazepam	2764	IV	N	Centrax
Pregabalin	2782	V	N	Lyrica
Proheptazine	9643	I	Υ	
Properidine	9644	I	Υ	
Propiram	9649	1	Υ	Algeril
Prostanozol (17beta-hydroxy-5alpha-androstano[3,2-c]pyrazole)	4000	III	N	Prostanozol; [3,2-c]pyrazole-5α-androstan-17β-ol
Psilocybin	7437	1	N	Constituent of "Magic mushrooms"
Psilocyn	7438	I	N	Psilocin, constituent of "Magic mushrooms"
Pyrovalerone	1485	V	N	Centroton, Thymergix
Quazepam	2881	IV	N	Doral
Racemethorphan	9732	Ш	Υ	
Racemoramide	9645	I	Υ	
Racemorphan	9733	П	Υ	Dromoran
Remifentanil	9739	II	Y	Ultiva
Secobarbital	2315	П	N	Seconal, Tuinal
Secobarbital & noncontrolled active ingred	2316	Ш	N	
Secobarbital suppository dosage form	2316	III	N	
Sibutramine	1675	IV	N	Meridia
SPA	1635	IV	N	1-dimethylamino-1,2-diphenylethane, Lefetamine
SR-18 (Also known as RCS-8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole)	- 7008	I	N	SR-18 and RCS-8
SR-19 (Also known as RCS-4) (1-Pentyl-3-[(4- methoxy)-benzoyl] indole	7104	I	N	SR-19 and RCS-4
Stanozolol (17alpha-methyl-17beta-hydroxy-5alpha- androst-2-eno[3,2-c]-pyrazole)	4000	III	N	Winstrol, Winstrol-V
Stenbolone (17beta-hydroxy-2-methyl5alpha-androst- 1-en-3-one)	4000	III	N	
Stimulant compounds previously excepted	1405	III	N	Mediatric
Sufentanil	9740	Ш	Υ	Sufenta

SUBSTANCE	DEA NUMBER	CSA SCH	NARC	OTHER NAMES
Sulfondiethylmethane	2600	III	N	
Sulfonethylmethane	2605	III	N	
Sulfonmethane	2610	III	N	
Suvorexant	2223	IV	N	MK-4305, [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
Talbutal	2100	III	N	Lotusate
Tapentadol	9780	П	Υ	
Temazepam	2925	IV	N	Restoril
Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta- 1,4-dien-17-oic acid lactone)	4000	III	N	Teolit, Teslac
Testosterone (17beta-hydroxyandrost-4-en-3-one)	4000	III	N	Android-T, Androlan, Depotest, Delatestryl
Tetrahydrocannabinols	7370	I	N	THC, Delta-8 THC, Delta-9 THC, dronabinol and others
Tetrahydrogestrinone (13beta,17alpha-diethyl-17beta- hydroxygon-4,9,11-trien-3-one)	4000	III	N	THG
Tetrazepam	2886	IV	N	Myolastan, Musaril
Thebacon	9315	I	Υ	Acetylhydrocodone, Acedicon, Thebacetyl
Thebaine	9333	П	Υ	Precursor of many narcotics
Thiafentanil	9729	П	Υ	Thianil
Thiamylal	2100	III	N	Surital
Thiofentanyl	9835	I	Υ	Chine white, fentanyl
Thiopental	2100	III	N	Pentothal
THJ-2201 [1-(5-fluoropentyl)-1H-indazol-3- yl](naphthalen-1-yl)methanone	7024	I	N	THJ-2201
Tiletamine & Zolazepam Combination Product	7295	III	N	Telazol
Tilidine	9750	I	Υ	Tilidate, Valoron, Kitadol, Lak, Tilsa
Tramadol (2-[(dimethylamino)methyl]-1-(3- methoxyphenyl)cyclohexanol)	9752	IV	Y	Tramadol
Trenbolone (17beta-hydroxyestr-4,9,11-trien-3-one)	4000	III	N	Finaplix-S, Finajet, Parabolan
Triazolam	2887	IV	N	Halcion
Trimeperidine	9646	I	Υ	Promedolum
U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]- N-methylbenzamide)	9547	I	Υ	U-47700
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3- tetramethylcyclopropyl)methanone	7144	I	N	UR-144
Valeryl fentanyl	9840	I	Υ	N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide
Vinbarbital	2100	III	N	Delvinal, vinbarbitone
Zaleplon	2781	IV	N	Sonata
Zolpidem	2783	IV	N	Ambien, Ivadal, Stilnoct, Stilnox
Zopiclone	2784	IV	N	Lunesta

DEA CSA
SUBSTANCE NUMBER SCH NARC OTHER NAMES